bit.bio
Biotech · United Kingdom · Founded 2016 · private
bit.bio cut around a quarter of its staff in 2025, wound down its own cell therapy programmes and raised a $50m Series C led by M&G in January 2026 as a supplier of defined human cells rather than a drug developer.
The record
0 figures · 1 rounds · 1 backers · 2 feed items
Every one of them carries its source, its date, and its age when it has one. Reading the record takes a free account; the account is how you keep a watchlist.